Clothing combines maximum biological protection with unparalleled comfort levels, helping frontline responders to stay safe and focus on their frontline roles

DuPont (NYSE: DD) has launched the DuPont™ Tyvek® ES workwear range to offer emergency services personnel and patients the highest levels of protection against biological risks, paired with exceptional fit. Based on DuPont’s proven breathable materials technology, the new Tyvek® ES range of gowns and suits provides an optimal balance between protection and comfort for those working in emergency medical services, including frontline responders, paramedics, and ambulance staff.

Commenting on the launch, Chloé Caux-Wetherell, EMEA Marketing Manager for DuPont Personal Protection, explains: “Infectious diseases like COVID and SARS present a growing challenge to society, and emergency medical services personnel are on the front lines. DuPont has developed its new Tyvek® ES range to help mitigate the risk of biological transmission without causing discomfort or overheating for the wearer. This optimal combination of protection and comfort can enable emergency medical services personnel to focus on their frontline roles, knowing they are protected from infection risks for themselves and their patients.”

The Tyvek® ES range is easily distinguishable from other protective clothing by its distinctive blue and red chest label against white material. The range initially includes four garment options, all characterized by proven levels of breathability and durability of the nonwoven Tyvek® material, along with exceptional antistatic properties. All garments in this range meet Category III protection up to Type 3-B, 5-B, and 6-B standards.

The Tyvek® 500 ES gown and Tyvek® 500 ES suits are designed for use in situations with low biological exposure risk or where the risk is defined (BSL-3 or lower). Examples include transporting an infected patient, triage, or setting up refugee camps. The gown features a collar, integrated waist ties, and knit cuffs for enhanced comfort under gloves. The suit has a front zipper closure, along with elastic around the hood, waist, cuffs, and ankles. Both these suits offer maximum breathability combined with a biobarrier that includes antivirus protection according to ISO 16604 Class 2 and meets performance requirements of EN 13795-1.

Additionally, the Tyvek® 500 AV suit is for low-risk applications BSL-3 and lower, but is innovative with an antiviral coating that adds an extra layer of protection to help eliminate viruses or bacteria upon contact with the garment. This suit meets ISO 18184 standards and offers 99.99% efficacy against SARS-CoV-2, making it ideal for hospital use with severely ill patients or where maximum infection control measures are required, such as hospital-acquired infections (HAI).

The Tyvek® 800 ES suit is for higher-risk applications of BSL-3 and above. It offers the highest levels of protection and is used in circumstances where the risk is unknown or where there is a high risk of exposure to bodily fluids. Examples include road accidents, medical emergencies, and humanitarian disasters. In addition to the zipper closure and elastic at hood, cuffs, waist, and ankles, the Tyvek® 800 ES suit features a storm flap on the collar and covered pass-through elastic for additional protection. It offers the best breathability for a Type 3 garment, including antivirus protection according to ISO 16604 Class 5, and is classified as Category III Type 3-B, 4-B, 5-B, and 6-B.

For more information, visit the DuPont™ SafeSPEC™ website: link.

About DuPont

DuPont (NYSE: DD) is a leading global innovation company that develops and manufactures materials and technological solutions contributing to the transformation of industries and everyday life. The company’s personnel leverage scientific knowledge and acquired expertise to help customers develop their most innovative ideas and create groundbreaking innovations in key markets including electronics, transportation, building and construction, water, healthcare, and worker safety. Further information is available at: www.dupont.com. Investors can access information through the Investor Relations section of the website at: investors.dupont.com.

Sources

• DuPont press release